Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.02.19
Views: 1223

Dr Nicholas van As - The Royal Marsden NHS Foundation Trust, London, UK

Dr Nicholas van As speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about analysis of acute toxicity from the randomised phase III PACE-B trial comparing tereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localised prostate cancer.

He explains that the main difference between SBRT and CFMHRT is the dose as using modern techniques you can deliver larger doses more accurately and safely while increasing the effectiveness.

Dr van As reveals that SBRT, which was the lower dose of the two, had lower toxicity than expected and that importantly there was no statistical difference between toxicity of the two.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation